Antenatal dexamethasone,
does it really help with Reduced neonatal death and stillbirth-or-neonatal-death in low-resource hospitals?
research showsThe grade is B with 76 points. WHO ACTION-I studied 2,852 women and 3,070 fetuses at 29 hospitals in five countries in a double-blind placebo-controlled trial. Neonatal death by day 28 was 19.6% versus 23.5%, RR 0.84 (95% CI 0.72–0.97), an absolute 3.9-point reduction. Stillbirth or neonatal death was 25.7% versus 29.2%, RR 0.88 (0.78–0.99). Both coprimary efficacy outcomes succeeded in one large trial that stopped early for benefit.
ads claimThis is not evidence to inject dexamethasone anywhere labeled low-resource. Applicability requires the hospital conditions, diagnostic accuracy, infection exclusion, and newborn-care capacity used in the trial.
Useful facts when choosing a product
- The regimen was intramuscular dexamethasone 6 mg every 12 hours for up to four doses.
- Fresenius Kabi–Labesfal produced the procured drug and placebo, without a reported research role.
- Maternal infection met the prespecified noninferiority boundary.
What the research actually shows
Women at 29 secondary- and tertiary-level hospitals in Bangladesh, India, Kenya, Nigeria, and Pakistan received dexamethasone or identical placebo. WHO sponsored the trial, supported by a grant from the Bill & Melinda Gates Foundation, a private nonprofit foundation, and the UNDP–UNFPA–UNICEF–WHO–World Bank Special Programme. Fresenius Kabi–Labesfal produced the purchased trial drug and identical placebo; no manufacturer role in the research was reported. Early stopping for benefit was counted as one design limitation.
Why this is classified as B (76)
A large nonprofit- and international-program-funded double-blind trial met both coprimary mortality outcomes and the prespecified 15% threshold; single-trial evidence with early stopping gives B with 76 points.
Counterpoint. The result should not be generalized beyond hospitals able to reproduce the trial's care conditions.
Rejudgment record. Cross-check applied — A large double-blind trial funded by a nonprofit foundation and international program met both coprimary mortality outcomes and its prespecified 15% relative-reduction threshold, but was a single trial stopped early for benefit
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced neonatal death by 28 days | B | Rates were 19.6% versus 23.5%, RR 0.84. |
| Reduced stillbirth or neonatal death | B | Rates were 25.7% versus 29.2%, RR 0.88. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| WHO ACTION Trials Collaborators 2020 ACTION-I | Double-blind placebo-controlled randomized trial at 29 hospitals in five countries | 3,070 | A grant from the private nonprofit Bill & Melinda Gates Foundation and the UNDP–UNFPA–UNICEF–WHO–World Bank Special Programme | Coprimary outcomes of neonatal death by 28 days and stillbirth or neonatal death | 19.6% versus 23.5%, RR 0.84 (95% CI 0.72–0.97), absolute difference -3.9 points; 25.7% versus 29.2%, RR 0.88 (0.78–0.99); stopped early for benefit | Single large hard-outcome trial under low-resource hospital conditions |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Antenatal dexamethasone x mortality reduction after early preterm birth in low-resource hospitals — Evidence Grade B·76. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/antenatal-dexamethasone-low-resource-hospitals-early-preterm-mortality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.